Ritesh B. Tichkule, Ph.D.
|2013||Chemistry & Chemical Biology||Northeastern University, Boston, MA, United States|
Mean distance: (not calculated yet)
ParentsSign in to add mentor
ChildrenSign in to add trainee
CollaboratorsSign in to add collaborator
BETA: Related publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
|Salaga M, Binienda A, Tichkule RB, et al. (2019) Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. J. Pharmacol. (2018), 836 34-43]. European Journal of Pharmacology. 172656|
|Salaga M, Binienda A, Tichkule RB, et al. (2018) The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. European Journal of Pharmacology|
|Kulkarni PM, Kulkarni AR, Korde A, et al. (2015) Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s). Journal of Medicinal Chemistry|
|Fichna J, Bawa M, Thakur GA, et al. (2014) Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors. Plos One. 9: e109115|
|Gamage TF, Ignatowska-Jankowska BM, Wiley JL, et al. (2014) In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behavioural Pharmacology. 25: 182-5|
|Thakur GA, Tichkule R, Bajaj S, et al. (2009) Latest advances in cannabinoid receptor agonists. Expert Opinion On Therapeutic Patents. 19: 1647-73|